Recent

% | $
Quotes you view appear here for quick access.

NQ Mobile Inc. Message Board

andrewko1977 7 posts  |  Last Activity: Aug 16, 2016 9:53 PM Member since: Aug 8, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    QUESTION: SEC Filing=HEAT Merger??

    by diannalee777 Aug 16, 2016 11:16 AM
    andrewko1977 andrewko1977 Aug 16, 2016 9:53 PM Flag

    I'm not invested in HTBX but based on what I know, they are somewhat similar to ONCS. Both companies awaiting major catalyst in coming months - HTBX's lead P2 non-muscle invasive bladder cancer program.

    Having say that, if I were a short term guy, I would buy and hold both and whichever pops first, sell and load up on the other. To me, invest in just one tiny bio stock is enough. It looks like they gave back some of recent gains today.

  • Reply to

    QUESTION: SEC Filing=HEAT Merger??

    by diannalee777 Aug 16, 2016 11:16 AM
    andrewko1977 andrewko1977 Aug 16, 2016 2:31 PM Flag

    Well, who really knows what's going on but here is my guess.

    It is possible but I think recent S3 shelf registration is for future dilution, as requested, based on the previous S3 submitted 18 April 2014 for up to 75M. I haven't counted recent dilution total but oncs may well reached 75M ceiling so needed another on for future use.

    As you are well aware, good data doesn't grantee partnership so just in case, they need to ready for other options. However, I tend to believe a partnership is very possible, actally, it's about time, ripe for a partnership. Some folks think Merck may even buy oncs while it's extremely inexpensive - look at current MC of $31M!!!!

    Not all partnership are equal. We née something similar or better than most recent ADXS deal with Amgen - 40M upfront cash, 25M common stock purchase, up to 475M milestone pymt, royalty pymt.....

    I am little bit disappointed today PPS action thus far. Up only 5 cents! Last night news along with WSJ article may not hit to the street but it gave me chance to accumulate little more today. However, I feel better than ever over oncs progresses so soon or later my patience will pay off.

    Sentiment: Strong Buy

  • This is very positive news - from this publication of data, we will likely be looking at a positive response rate in the combo study.

    SAN DIEGO, Aug. 15, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the publication of research showing that partially exhausted CD8+ cells infiltrating melanoma tumors accurately predicted most patients' responses to anti-PD-1 therapies. The findings, published in the Journal of Clinical Investigation, show that the response to pembrolizumab strongly correlated to the percent of CD8+ tumor-infiltrating lymphocytes (TILs) that expressed high levels of both PD-1 and CTLA-4. The study was led by University of California, San Francisco (UCSF) researchers and physicians. This exhaustion marker is currently being used to select patients for the ongoing Phase II investigator-sponsored clinical trial evaluating the combination of OncoSec's investigational therapy, ImmunoPulse® IL-12, and the approved anti-PD-1 therapy, pembrolizumab, in patients with unresectable metastatic melanoma.
    With tumor samples from a discovery cohort of 20 patients who had received anti-PD-1 therapy, researchers used multiparameter flow cytometry to sort cells according to immune biomarker expression in the study. Researchers examined CD8+ cells to see whether they expressed PD-1, CTLA-4, and other proteins. The number of partially exhausted CD8+ cells in tumors that expressed high levels of both PD-1 and CTLA-4 was a reliable biomarker of response to anti-PD-1 therapy, with response defined by standard RECISTv1.1 criteria. This observation was confirmed in a separate validation cohort of 20 patients.
    "This paper supports the concept that the 'target cell' of anti-PD-1 monoclonal antibodies (mAb) is the partially exhausted CD8+ T-cell within the tumor, which can be readily quantified using flow cytometry," said Robert H. Pierce, MD, OncoSec Chief Scientific Strategist and co-author of the paper. "We've taken advantage of this assay's ability to strongly predict patients, who are unlikely to respond to anti-PD-1 mAb monotherapy, and select these patients in our ongoing Phase II trial, where we are combining intratumoral electroporation of plasmid IL-12 and pembrolizumab."
    "These findings represent an advance in the field of cancer immunotherapy," said Adil Daud, MD, director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center. "Many tests examining PD-L1 levels in tumor tissue can only modestly discriminate between responders and non-responders. This analysis accurately predicts response to anti-PD-1 therapy and can be utilized in the clinic to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition."
    OncoSec is assessing the anti-tumor activity, safety, and tolerability of the combination of ImmunoPulse® IL-12 and pembrolizumab in melanoma patients in a Phase II clinical trial sponsored by UCSF. This multi-center, open-label, single-arm trial is the first study to use UCSF's T-cell exhaustion marker assay. The study will test the hypothesis as to whether the addition of ImmunoPulse® IL-12 to pembrolizumab can increase the response rate in melanoma patients, who have a low likelihood of responding to monotherapy with anti-PD-1 blockade. The key endpoints of the study include: best overall response rate (BORR) by RECIST v1.1 and immune-related Response Criteria (irRC); safety and tolerability; duration of response; 24-week landmark progression-free survival; median progression-free survival; and overall survival. OncoSec expects to present data from this trial in the second half of 2016.

    Sentiment: Strong Buy

  • andrewko1977 andrewko1977 Aug 15, 2016 1:33 PM Flag

    Vanguard added 13k shares, renaissance added 80k shares, and Nomura holdings added 29k shares.
    Sabby holding 608k shares. It looks like slow accumulations going on including insiders.

  • andrewko1977 andrewko1977 Aug 15, 2016 12:56 PM Flag

    I hear you. we're pretty much shares same understanding. I also involvd with this company last 3 years. The only difference is I am keep on holding my shares and added some more as it down to lower my average down. I am not good at in and out stocks neither have time to closely monitor daily/hourly bases. On top of that, my investment horizon can be several more years so as long as company fundamental intact, I can wait. Yes, i am not happy but I rather have my heavy invested company race with full speed that requires money - dilution. Oh! Believe me, there are still plent of longs, on top of messed up yahoo message board, they just don't have much to say.

    Having say that i really appreciate your candid assessment. Good luck with your investment.

    Sentiment: Strong Buy

  • The last time they filed S3 was 18 April 2014 for up to $75M. They have to raise more money if they can't get partnership after release data in any month now. If you're not happy about raising money, you shouldn't even buy small cap bio stocks - w/o revenue, how else they will pay for ongoing studies? In this case, they filed S3 because they have to keeping option s open just in case.

    ONCS also filed two separate form 4 on 5 Aug 2016 to report stock purchase by Punit and Mohan-Peterson. Not much but this definitely a encouraging developmrnt. Punit now own 765,501 shares and 153,250 shares for mohan-peterson.

    Sentiment: Strong Buy

  • Reply to

    SEC Form S-3 Filed DILUTION

    by diannalee777 Aug 10, 2016 11:20 AM
    andrewko1977 andrewko1977 Aug 10, 2016 12:20 PM Flag

    Form S-3 not necessarily dilution but insiders transactions. I knew they filed S3 yesterday evening.

    Sentiment: Strong Buy

NQ
4.3311+0.0011(+0.03%)1:38 PMEDT